Trandolapril delayed persistent microalbuminuria in hypertension, type 2 diabetes, and normoalbuminuria: COMMENTARY

Kudva, Yogish; Hunt, Dereck
May 2005
ACP Journal Club;May/Jun2005, Vol. 142 Issue 3, p65
Academic Journal
The article reports that the trial by certain researchers contributes to the current evidence by showing that the antiproteinuric effects of ACE inhibitors begin even when albumin excretion rates are normal in patients with hypertension and type 2 diabetes. Trandolapril (but not verapamil) delayed the onset of persistent microalbuminuria. These results are consistent with those of the Heart Outcomes Prevention Evaluation study, which showed that patients with diabetes and ≥ 1 other cardiovascular risk factor benefited from ramipril.


Related Articles

  • Management of Blood Pressure in Patients With Diabetes. Grossman, Ehud; Messerli, Franz H. // American Journal of Hypertension;Aug2011, Vol. 24 Issue 8, p863 

    Hypertension is a major modifiable risk factor for cardiovascular morbidity and mortality in patients with diabetes. Lowering blood pressure (BP) to 135/85 mm Hg is the main goal of treatment. A nonpharmcologic approach is recommended in all patients. If BP levels remain above the target despite...

  • Hypertension, Prehypertension and Blood Pressure Related Diseases. Chemla, D.; Antony, I.; Plamann, K.; Abastado, P.; Nitenberg, A. // Immunology, Endocrine & Metabolic Agents - Medicinal Chemistry;Aug2006, Vol. 6 Issue 4, p319 

    Hypertension is defined as either an elevation of systolic blood pressure (SBP) to ≥ 140 mmHg and/or elevation of diastolic blood pressure (DBP) to ≥ 90 mmHg for adults. Hypertension is a frequent, age-related disorder and a major risk factor for stroke, coronary heart disease, heart...

  • Calcium Channel Blockers in Obesity-Related Hypertension. Masuo, Kazuko; Lambert, Gavin W. // Immunology, Endocrine & Metabolic Agents - Medicinal Chemistry;Jun2010, Vol. 10 Issue 2, p66 

    No abstract available.

  • Hypertension management algorithm for type 2 diabetic patients applied in primary care. Viana, Luciana V.; Leitão, Cristiane B.; Grillo, Maria F.; Rocha, Ennio P. C. C.; Brenner, Juliana K.; Friedman, Rogerio; Gross, Jorge L. // Diabetology & Metabolic Syndrome;2013, Vol. 5 Issue 1, p1 

    Background: Hypertension frequently coexists with type 2 diabetes (DM), and increases the risk of cardiovascular outcomes. The aim of the study was to obtain/maintain blood pressure (BP) goals (ADA/JNC 7) according to a stepwise algorithm using the medication supplied by the Brazilian...

  • Effects of Manidipine and its Combination with an ACE Inhibitor on Insulin Sensitivity and Metabolic, Inflammatory and Prothrombotic Markers in Hypertensive Patients with Metabolic Syndrome.  // Clinical Drug Investigation;2011, Vol. 31 Issue 3, p201 

    No abstract available.

  • The Clinical Significance of New-Onset Diabetes Mellitus in Hypertension. Verdecchia, Paolo; Angeli, Fabio; Garofoli, Marta; Reboldi, Gianpaolo // High Blood Pressure & Cardiovascular Prevention;Feb2008, Vol. 15 Issue 1, p1 

    Several intervention trials found that some antihypertensive drugs, mostly ACE inhibitors, calcium-channel blockers and angiotensin II receptor blockers, are associated to a lesser risk of developing diabetes mellitus in comparison with other drug classes, including diuretics and β-blockers....

  • Treatment of zygomycosis: current and new options.  // Journal of Antimicrobial Chemotherapy (JAC);Jan2008, Vol. 61, pi35 

    Zygomycosis is a frequently lethal invasive infection in high-risk patients such as the immunocompromised [especially haematopoietic stem cell transplant (HSCT) recipients] and patients with type 2 diabetes mellitus. However, zygomycosis has also been reported in individuals without known risk...

  • Effect of combination tablets containing amlodipine 10 mg and irbesartan 100 mg on blood pressure and cardiovascular risk factors in patients with hypertension. Shusuke Yagi; Akira Takashima; Minoru Mitsugi; Toshihiro Wada; Junko Hotchi; Ken-ichi Aihara; Tomoya Hara; Masayoshi Ishida; Daiju Fukuda; Takayuki Ise; Koji Yamaguchi; Takeshi Tobiume; Takashi Iwase; Hirotsugu Yamada; Takeshi Soeki; Tetsuzo Wakatsuki; Michio Shimabukuro; Masashi Akaike; Masataka Sata // Therapeutics & Clinical Risk Management;2015, Vol. 11, p83 

    Background: Hypertension is one of the major risk factors for cardiovascular and cerebrovascular disease and mortality. Patients who receive insufficient doses of antihypertensive agents or who are poorly adherent to multidrug treatment regimens often fail to achieve adequate blood pressure (BP)...

  • Amlodipine/Valsartan: Fixed-Dose Combination in Hypertension. Plosker, Greg L; Robinson, Dean M // Drugs;2008, Vol. 68 Issue 3, p373 

    Amlodipine, a dihydropyridine calcium channel blocker, and valsartan, an angiotensin II receptor blocker, are established antihypertensive agents. Fixed-dose combinations of amlodipine/valsartan are available in several European countries and in the US. Individual dose titration with amlodipine...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics